Faculty
BIOGRAPHY
Guoan Chen, M.D., Ph.D., Associate Professor in the School of Medicine, Southern University of Science and Technology. Dr. Chen received his medical degree from Xi'an Jiaotong University in Xi’an, China in 1986 and finished his M.S. program in Pulmonary Medicine in Xi’an Jiaotong University in 1992. He received his Ph.D. in oncology from Peking Union Medical College in 1999. In 2000, he joined Professor David G. Beer’s Tumor Biology Laboratory as a Research Fellow and completed his post-doctoral training in tumor molecular biology at the University of Michigan and was promoted to the faculty as Research Investigator at the University of Michigan Medical School in 2004. He was promoted to Research Assistant Professor in 2010, and Associate Research Scientist in 2017. Dr. Chen’s research interests are focused within the fields of genomics, proteomics, and bioinformatics in lung cancer. He utilizes the state of the art molecular technologies and approaches, including gene expression microarray, SNP array, miRNA array and RNA deep sequencing, etc. to identify molecular changes for patient survival, the early diagnosis and the molecular mechanism in lung cancer progression. He currently worked on micro-RNAs, long non-coding RNAs, and circRNAs for lung cancer diagnosis and prognosis, as well as the functional, mechanistic and therapeutic application of these molecules in lung cancer. He has published over 80 SCI research articles, such as Nature Medicine, Nature Biotechnology, Cancer Cell, JNCI，J Clinical Investigation, Nature Communications, Cancer Research, Clinical Cancer Research, J Thoracic Oncology，Genome Research， Developmental Cell, PNAS, and has been cited more than 8800 times with h-index 41, i10-index 64 (Google Scholar).
RESEARCH interests:
Molecular biology of lung cancer
Functional genomics
Non-coding RNA
The mechanisms of tumor metastasis and drug resistance
TEACHING
2/2019 – present courses, Medical Molecular Biology for Clinical Medicine undergraduate student, Southern University of Science and Technology
2/2019 – present courses, Integrated Biomedical Experiments for Biomedical Science undergraduate student, Southern University of Science and Technology
2/2019 – present courses, Physiology and Pathophysiology for Biomedical Science and Clinical Medicine undergraduate student, Southern University of Science and Technology
2010 - 2018 Mentor for 2-4 visiting scholars/research fellows/each year in the lab for daily research work.
1993 – 1994 courses, Internal Medicine (180 hours) and Diagnostics (162 hours) for150 medical students, Xi’an, China.
1986 – 1996 Mentoring of M4 students, residents, postdoctoral research fellows in performing clinical and research work.
EDUCATION
9/1981-7/1986 B.S. in Medicine, Xi'an Medical University (Xi’an Jiaotong University), Xi'an, China.
9/1988-6/1992 M.S. in Pulmonary Medicine, Xi'an Medical University (Xi’an Jiaotong University), Xi'an, China. (Mentor: Dechang Yang, M.D.)
9/1996-6/1999 Ph.D. in Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. (Mentor: Yan Sun, M.D.)
POSTDOCTORAL TRAINING
3/2000-1/2003 Postdoctoral research fellow, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA. (Mentor: David G. Beer, Ph.D.)
ACADEMIC APPOINTMENTS
7/1986-6/1993 Resident physician, Internal Medicine of the Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China
7/1993-8/1996 Attending physician/Assistant Professor of Respiratory Department, The Second Hospital of Xi'an Jiaotong University, Xi'an, China.
6/1999-2/2000 Attending physician/Assistant professor, The Department of Respiratory, The Second Hospital of Xi’an Jiaotong University, Xi'an, China
2/2003-10/2004 Research Associate II, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
11/2004- 8/2010 Research Investigator, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
9/2010- 8/2017 Research Assistant Professor, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
9/2017 – 10/2018 Associate Research Scientist, The Department of Surgery, University of Michigan, Ann Arbor, Michigan, U.S.A.
10/2018 – present Associate Professor, School of Medicine, Southern University of Science
and Technology
PUBLICATION ，in recent 10 years:
Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG, Chang AC. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res. 2010 Apr 1;16(7):2009-21. PMID: 20332323 (IF:10.199).
Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M, Arima C, Travis WD, Yatabe Y, Takahashi T, Brambilla E, Beer DG.Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One. 2010 Jul 22; 5(7): PMID: 20661423 (IF:2.766).
Yu J, Cao Q, Yu J, Wu L, Dallol A, Li J, Chen G, Grasso C, Cao X, Lonigro RJ, Varambally S, Mehra R, Palanisamy N, Wu JY, Latif F, Chinnaiyan AM. The neuronal repellent SLIT2 is target for repression by EZH2 in prostate cancer. 2010 Sep 30;29(39):5370-80. PMID:20622896 (IF:6.854).
Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, Wang Z, Thomas DG, Giordano TJ, Lin L, Brenner DE, Beer DG, Ramnath N. CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. Clin Cancer Res. 2010 Dec 17. PMID: 21169243 (IF:10.199).
Meng H*,Chen G*, Zhang X, Wang Z, Thomas DG, Giordano TJ, Beer DG, Wang MM. Stromal LRP1 in Lung Adenocarcinoma Predicts Clinical Outcome. Clin Cancer Res. 2011 Apr 15;17(8):2426-33. PMID: 21325077 (* co-first authors) (IF:10.199).
Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. 2011 Jul;13(7):570-8. PMID: 21750651 (IF:4.994).
Gong HC, Wang S, Mayer G, Chen G, Leesman G, Singh S, and Beer DG. Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer. International Journal of Proteomics,2011:215496. PMID:22091388 .
Chen G, Kim S, Taylor JM, Wang Z, Lee O, Ramnath N, Reddy RM, Lin J, Chang AC, Orringer MB, Beer DG. Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol. 2011 Sep; 6(9):1481-7. PMID: 21792073 (IF:12.460).
Chen G, Beer DG. Response to translating cancer complexity to clinical decisions. J Thorac Oncol. 2011 Sep;6(9):1456-7. PMID: 21849851(IF:12.460).
Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, Zhao L, Simpson RU, Thomas DG, Giordano TJ, Brenner DE, Hollis B, Beer DG, Ramnath N. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer. 2012 May 5. PMID: 22564539 (IF:4.486).
Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha MS. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res. 2013 Feb 26. PMID:23444212 (IF:10.199).
Li CM, Chen G, Dayton TL, Kim-Kiselak C, Hoersch S, Whittaker CA, Bronson RT, Beer DG, Winslow MM, Jacks T. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes &2013 Jul 15;27(14):1557-67. PMID: 23873940 (IF:9.462).
Grabauskiene S, Bergeron EJ, Chen G, Chang AC, Lin J, Thomas DG, Giordano TJ, Beer DG, Morgan MA, Reddy RM. CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells. Lung Cancer. 2013 Sep 23.[Epub ahead of print] PMID:24113549 (IF:4.486).
Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M. A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer. J Clin Oncol. 2013 Nov 10;31(32):4140-7. PMID: 24081945 (IF:26.303).
Nadal E, Chen G*, Gallegos M, Lin L, Ferrer-Torres D, Truini A, Wang Z, Lin J, Reddy RM, Llatjos R, Escobar I, Moya J, Chang AC, Cardenal F, Capellà G, Beer DG. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.Clin Cancer Res. 2013 Dec 15;19(24):6842-52. PMID: 24130071. (*Co-corresponding author) (IF:10.199).
Grabauskiene S, Bergeron EJ, Chen G, Thomas DG, Giordano TJ, Beer DG, Morgan MA, Reddy RM. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer. J Surg Res. 2014 Mar; 187(1):6-13. PMID: 24418519 (IF:2.051).
Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G, Xu J, Zhao L, Thomas D, Beer DG, Sun Y. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J Clin Invest. 2014 Feb 3;124(2):835-46. PMID: 24430184 (IF:13.251).
Shukla S, Allam US, Ahsan A, Chen G, Krishnamurthy PM, Marsh K, Rumschlag M, Shankar S, Whitehead C, Schipper M, Basrur V, Southworth DR, Chinnaiyan AM, Rehemtulla A, Beer DG, Lawrence TS, Nyati MK, Ray D. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. 2014 Feb;16(2):115-28. PMID: 24709419 (IF:4.994).
Reka AK*, Chen G*, Jones RC, Amunugama R, Kim S, Karnovsky A, Standiford TJ, Beer DG, Omenn GS, Keshamouni VG. Epithelial-mesenchymal Transition Associated Secretory Phenotype Predicts Survival in Lung Cancer Patients. 2014 Feb; 16 (2):115-28. PMID: 24510113. (* co-first authors) (IF:5.072).
Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, Malumbres M, Letai A, Kirschner MW, Sun Y, Wei W. APC (Cdc20) Suppresses Apoptosis through Targeting Bim for Ubiquitination and Destruction. Dev Cell. 2014 May 27; 29(4):377-91. PMID: 24871945(IF:9.616).
Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, Chang AC, Beer DG, Chen G*. A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma. Clin Cancer Res. 2014 Jun 15; 20(12):3107-17. PMID: 24833665 (*Corresponding author) (IF:10.199).
Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, Kalemkerian GP, Brenner D, Lin J, Reddy RM, Chang AC, Capellà G, Cardenal F, Beer DG, Ramnath N. KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2014 Aug 28. PMID: 25170638(IF:12.460).
Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy RM, Azizi E, Fouladdel S, Chang AC, Lin L, Jiang H, Waghray M, Luker G, Simeone DM, Wicha MS, Beer DG, Ramnath N, Nagrath S. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014 Dec 15;5(23):12383-97. PMID: 25474037 (IF:5.168).
Dhanasekaran SM*, Alejandro Balbin O*, Chen G*, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014 Dec 22;5:5893. PMID: (* co-first authors) (IF:12.353).
Balbin OA, Malik R, Dhanasekaran SM, Prensner JR, Cao X, Wu YM, Robinson D, Wang R, Chen G, Beer DG, Nesvizhskii AI, Chinnaiyan AM. The landscape of antisense gene expression in human cancers. Genome Res. 2015 Jul;25(7):1068-79. PMID:26063736 (IF:10.101).
He Y, Wang L, Liu W, Zhong J, Bai S, Wang Z, Thomas DG, Lin J, Reddy RM, Ramnath N, Carrott PW, Lynch WR, Orringer MB, Chang AC, Beer DG, Chen G*. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. Sci Rep. 2015 Jun 19;5:11471. PMID: 26088427 (*Corresponding author) (IF:4.122).
Goswami MT*, Chen G*, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. 2015 Sep 15; 6(27):23445-61. PMID: 26140362 (* co-first authors) (IF:5.168).
Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG, Chen G*. A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep. 2015 Jul 23; 5:12464. PMID: 26202143 (*Corresponding author) (IF:4.122).
Zhao L, Feng D, Chen G, Taylor JM. A unified Bayesian semiparametric approach to assess discrimination ability in survival analysis. Biometrics. 2015 Dec 17. PMID: 26676324 (IF:1.524).
Wang L, He Y, Liu W, Bai S, Xiao L, Zhang J, Dhanasekaran SM, Wang Z, Kalyana-Sundaram S, Balbin OA, Shukla S, Lu Y, Lin J, Reddy RM, Carrott PW Jr, Lynch WR, Chang AC, Chinnaiyan AM, Beer DG, Zhang J, Chen G*. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. 2016 Feb 5. PMID: 26862852 (*Corresponding author) (IF:5.168).
Zhang Y, Meng X, Shi H, Li W, Ming Z, Zhong Y, Deng W, Zhang Q, Fan N, Niu Z, Chen G, Yang S. The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinib. Am J Transl Res. 2016 Apr 15;8(4):1730-7. eCollection 2016. (IF:3.27).
Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N. Impact of Staging with Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans with Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol. 2016 Jun 17. PMID:27322696 (IF:3.424).
Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2016 Oct 5;109(1). doi: 10.1093/jnci/djw200. Print 2017 Jan.PMID:27707839 (IF:12.589).
Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z, Zhao L, Beer D, Ray D, Ramnath N. Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. J Thorac Oncol. 2017 Feb;12(2):269-280. doi: 10.1016/j.jtho.2016.10.010. Epub 2016 Oct 26. PMID:27793774 (IF:12.460).
Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, Liu P, Li H, Tan M, Xiong X, Sun Y. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017 Jan 16;8:14002. PMID: 28090088 (IF:12.353).
Zhang J, Feng S, Su W, Bai S, Xiao L, Wang L, Thomas DG, Lin J, Reddy RM, Carrott PW, Lynch WR, Chang AC, Beer DG, Guo YM, Chen G*. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep. 2017 Feb 15;7:42819. PMID: 28198463 (*Corresponding author) (IF:4.122).
Liu Y, Bu L, Li W, Wu W, Wang S, Diao X, Zhou J, Chen G, Yang S. Increased AAA-TOB3 correlates with lymph node metastasis and advanced stage of lung adenocarcinoma. Int J Biol Markers. 2017 Jun 15: PMID:28623644 (IF:1.449).
Feng S, Zhang J, Su W, Bai S, Xiao L, Chen X, Lin J, Reddy RM, Chang AC, Beer DG, Chen G*. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep. 2017 Jun 7;7(1):2982. PMID: 28592840 (*Corresponding author) (IF:4.122).
Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest. 2018 Jan 11. PMID: 29324443 (IF:13.251).
Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM, Orringer MB, Chang AC, Yang Z, Beer DG, Chen G*. Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018 Apr 18. PMID: 29669758 (*Corresponding author) (IF:9.130).
Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine. 2018 May 31. PMID: 29861409 (IF:6.680).
Raghunathan R, Cease K, Troeschel S, Zhao L, Gross M, Chen G, Chopra V, Ramnath N Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Managementand Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol.2018 May;41(5):513-518, PMID:27322696 (IF:3.424).
Heiden BT, Chen G, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, Zhao L, Beer DG, Reddy RM. 18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer. PloS One. 2018 Jul 2;13(7): PMID: 29966011 (IF:2.766).
Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signature for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 Jan;14(1):25-36. PMID: 30253973 (IF:12.460).
Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y, Zhang J, Beer DG, Yang Z, Chen G*. LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma. Aging (Albany NY). 2019 May 13;11(9):2812-2821. PMID: 31085800 (*Corresponding author) (IF:5.515).
Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205. PMID: 31101821 (IF:11.878).
Li L, Kang J, Zhang W, Cai L, Wang S, Liang Y, Jiang Y, Liu X, Zhang Y, Ruan H, Chen G, Wang M, Jia L.Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer. EBioMedicine. 2019 Jun 14. PMID: 31208947(IF:6.680)
Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S, Chen G*. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer. Int J Biol Sci. 2019 Jun 10;15(8):1712-1722. doi: 10.7150/ijbs.33986. eCollection 2019. PMID: 31360113 (*Corresponding author) (IF:4.06)
Chen X, Mao R, Su W, Yang X, Geng Q, Guo C, Wang Z, Wang J, Kresty LA, Beer DG, Chang AC, Chen G. Circular RNA circHIPK3 modulates autophagy via IR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. 2020 Apr;16(4):659-671. doi: 10.1080/15548627.2019.1634945. Epub 2019 Jun 28. PMID: 31232177 (*Corresponding author) (IF:11.059)
Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, Tzou D, Yang X, Huang X, Wu J, Chen X, Zou L, Yang Z, Chen G*. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany NY). 2019 Jul 10;11. doi: 10.18632/aging.102071. [Epub ahead of print] PMID: 31291201 (*Corresponding author) (IF: 5.515).
Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019 Sep 23. pii: 201905973. doi: 10.1073/pnas.1905973116. [Epub ahead of print] PMID: 31548378 (IF:9.58)
Yang X, Su W, Chen X, Geng Q, Zhai J, Shan H, Guo C, Wang Z, Fu H, Jiang H, Lin J, Lagisetty KH, Zhang J, Li Y, Yang S, Massion PP, Beer DG, Chang AC, Ramnath N, Chen G*. Validation of a serum 4-microRNA signature for the detection of lung cancer. Transl Lung Cancer Res. 2019 Oct;8(5):636-648. doi: 10.21037/tlcr.2019.09.11. PMID:31737499 (*Corresponding author) (IF: 4.81).
Xia Yang, Qiuhong Zhang, Wenmei Su, Ming Zhang, Hu Shan, Jie Zhang, Guoan Chen, Chunfang Guo, Yali Li. Expression level of serum miRNA-22 and its clinical significance in patients with lung cancer. International Journal of Respiration. 2019 Sep, 39(18), 1373-1378
Jiang Y, Cheng W, Li L, Zhou L, Liang Y, Zhang W, Chen W, Wang S, Zhao H, Chen G, Zhou W, Ji G, Zhang Y, Hoffman RM, Wang M, Jia L. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. Cell Biol Toxicol. 2020 Jan 6. doi: 10.1007/s10565-019-09503-6. [Epub ahead of print] PMID: 31907687 (IF: 5.1).
Lyu X, Zeng L, Zhang H, Ke Y, Liu X, Zhao N, Yuan J, Chen G, Yang S. Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. Life Sci. 2020 Jan 27:117366. doi: 10.1016/j.lfs.2020.117366. [Epub ahead of print], PMID: 32001266 (IF: 3.5).
Huang W, Ray P, Ji W, Wang Z, Nancarrow D, Chen G, Galban S, Lawrence TS, Beer DG, Rehemtulla A, Ramnath N, Ray D. The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independently of its catalytic activity. J Biol Chem. 2020 Mar 12. pii: jbc.RA119.011869. doi: 10.1074/jbc.RA119.011869. [Epub ahead of print] PMID: 32165494 (IF: 4.13).
Complete List of Published Work in MyBibliography: (83 out of 103):
https://www.ncbi.nlm.nih.gov/myncbi/1Z9MtLPgDMKQb/bibliography/public/
PATENTS
1. Methods and compositions for diagnosing lung cancer
Patent number: 7597890
Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.
Type: Grant
Filed: March 8, 2007
Date of Patent: October 6, 2009
Assignee: The Regents of the University of Michigan
Inventors: Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang
2. LUNG CANCER SIGNATURE
Publication number: 20120295803
Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.
Type: Application
Filed: May 16, 2012
Publication date: November 22, 2012
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors: David Beer, Jeremy Taylor, Guoan Chen, Sinae Kim
3. LUNG CANCER SIGNATURE
Publication number: 20150153346
Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.
Type: Application
Filed: November 13, 2014
Publication date: June 4, 2015
Inventors: Venkateshwar G. Keshamouni, Gilbert S. Omenn, Guoan Chen, David G. Beer, Theodore J. Standiford